Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-02T19:05:31.928Z Has data issue: false hasContentIssue false
  • English
  • Français

Oral prostacyclin enhances the pulmonary vasodilatory effect of nitric oxide in children with pulmonary hypertension

Published online by Cambridge University Press:  19 August 2008

Kei-ichiro Uese ,
Fukiko Ichida ,
Shin-ichi Tsubata ,
Ikuo Hashimoto ,
Yuji Hamamichi ,
Kazuaki Fukahara ,
Arata Murakami  and
Toshio Miyawaki
Kei-ichiro Uese
Affiliation:
Department of Pediatrics and the First Division of Surgery, Toyama Medical & Pharmaceutical University, Toyama, Japan
Fukiko Ichida*
Affiliation:
Department of Pediatrics and the First Division of Surgery, Toyama Medical & Pharmaceutical University, Toyama, Japan
Shin-ichi Tsubata
Affiliation:
Department of Pediatrics and the First Division of Surgery, Toyama Medical & Pharmaceutical University, Toyama, Japan
Ikuo Hashimoto
Affiliation:
Department of Pediatrics and the First Division of Surgery, Toyama Medical & Pharmaceutical University, Toyama, Japan
Yuji Hamamichi
Affiliation:
Department of Pediatrics and the First Division of Surgery, Toyama Medical & Pharmaceutical University, Toyama, Japan
Kazuaki Fukahara
Affiliation:
Department of Pediatrics and the First Division of Surgery, Toyama Medical & Pharmaceutical University, Toyama, Japan
Arata Murakami
Affiliation:
Department of Pediatrics and the First Division of Surgery, Toyama Medical & Pharmaceutical University, Toyama, Japan
Toshio Miyawaki
Affiliation:
Department of Pediatrics and the First Division of Surgery, Toyama Medical & Pharmaceutical University, Toyama, Japan
*
Fukiko Ichida, MD, Department of Pediatrics, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama, Toyama 930-01, Japan. Tel. 81-764-34-2281; Fax. 81-764-34-5029
Get access Rights & Permissions [Opens in a new window]

Abstract

To evaluate the potential efficacy of the combined administration of inhaled nitric oxide and oral beraprost sodium in producing pulmonary vasodilation, we studied 20 patients with pulmonary hypertension during cardiac catheterization. We also evaluated some of the mechanisms of vasodilation under these circumstances by investigating the levels of cyclic GMP and AMP in the pulmonary venous blood. A significant decrease in pulmonary vascular resistance was observed after the administration of nitric oxide (−37 ± 6%, p<0.01), and more intense decrease was observed after the combined administration of nitric oxide and beraprost sodium (−46 ± 6%, p<0.05). In addition, the ratio of pulmonary-to-systemic resistance also decreased to a greater extent with combined administration than with nitric oxide alone (−34 ± 6% vs −42 ± 7%, p<0.05). Conversely, systemic vascular resistance showed no change, neither after loading with nitric oxide nor after combined administration. Although equivalent increases in levels of cyclic GMP were observed after inhalation of nitric and the combined administration (mean 78% vs 65%), greater increases in levels of cyclic AMP were observed with the combined use (mean 15% vs 69%). Combined treatment with nitric oxide and beraprost sodium may prove markedly beneficial in patients with primary and postoperative pulmonary hypertension who do not respond adequately to inhalation of nitric oxide alone or conventional modes of treatment.

Keywords

Oral prostacyclin analoguenitric oxidecyclic GMPcyclic AMPpulmonary hypertension
Type
Young Investigators Award
Information
Cardiology in the Young , Volume 7 , Issue 4 , October 1997 , pp. 362 - 369
Copyright
Copyright © Cambridge University Press 1997

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Cohen, RA, Vanhoutte, PM. Endothelium-Dependent Hyperpolarization. Circulation 1995; 92: 3337–3349.CrossRefGoogle ScholarPubMed
2.Pepke-Zaba, J, Timothy, W, Higenbottam, A, Dinh-Xuan, T, Stone, D, Wallwork, J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338: 1173–1174.CrossRefGoogle ScholarPubMed
3.Roberts, JD Jr, Polaner, DM, Lange, P, Zapol, WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992; 340: 818–819.CrossRefGoogle ScholarPubMed
4.Kinsella, JP, Neish, SR, Ivy, DD, Shaffer, E, Abman, SH. Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide. J Pediatr 1993; 123: 103–108.CrossRefGoogle ScholarPubMed
5.Finner, NN, Etches, PC, Kamstra, B, Tierney, AJ, Peliowski, A, Ryan, A. Inhaled nitric oxide in infants reffered for extracorporeal membrane oxygenation: dose response. J Pediatr 1994; 124: 302–308.CrossRefGoogle Scholar
6.Abman, SH, Griebel, JL, Parker, DK, Schmidt, JM, Swanton, D, Kinsella, JP. Acute effects of inhaled nitric oxide in children with severe hypoxemic respiratory failure. J Pediatr 1994; 124: 881–888.CrossRefGoogle ScholarPubMed
7.Roberts, JD, Lang, P, Bigatello, LM, Vlahakes, GJ, Zapol, WM. Inhaled nitric oxide in congenital heart disease. Circulation 1993; 87: 447–453.CrossRefGoogle ScholarPubMed
8.Journois, D, Pouard, P, Mauriat, P, Malhere, T, Vouhe, P, Safran, D. Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects. J Thorac Cardiovasc Surg 1994; 107: 1129–1135.CrossRefGoogle ScholarPubMed
9.Miller, OI, Clermajer, DS, Deanfield, JE, Macrae, DJ. Very-low-dose inhaled nitric oxide: a selective pulmonary vasodilator after operations for congenital heart disease. J Thorac Cardiovasc Surg 1994; 108: 487–494.CrossRefGoogle ScholarPubMed
10.Goldman, AP, Delius, RE, Deanfield, JE, Macrae, DJ. Nitric oxide is superior to prostacyclin for pulmonary hypertension after cardiac operations. Ann Thorac Surg 1995; 60: 300–306.CrossRefGoogle ScholarPubMed
11.Day, RW, Lynch, JM, Shaddy, RE, Orsmond, GS. Pulmonary vasodilatory effects of 12 and 60 parts per million inhaled nitric oxide in children with ventricular septal defect. Am J Cardiol 1995; 75: 196–198.CrossRefGoogle ScholarPubMed
12.Beghetti, M, Habre, W, Friedli, B, Berner, M. Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients. Br Heart J 1995; 73: 65–68.CrossRefGoogle ScholarPubMed
13.Berner, M, Beghetti, M, Spahr-Schopfer, I, Oberhansli, I, Friedli, B. Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease. Am J Cardiol 1996; 77: 532–535.CrossRefGoogle ScholarPubMed
14.Gamillscheg, A, Zobel, G, Urlesberger, B, et al. Inhaled nitric oxide in patients with critical pulmonary perfusion after Fontan-type procedures and bidirectional Glenn anasromosis. J Thorac Cardiovasc Surg 1997; 113: 435–442.CrossRefGoogle Scholar
15.Bush, A, Busst, C, Booth, K, Knight, WB, Shinebourne, EA. Does prostacyclin enhance the selective pulmonary vasodila tor effect of oxygen in children with congenital heart disease? Circulation 1986; 74: 135–144.CrossRefGoogle Scholar
16.Bush, A, Busst, C, Knight, WB, Shineborne, EA. Modification of pulmonary hypertension secondary to congenital heart disease by prostacyclin therapy. Am Rev Respir Dis 1987; 136: 767–769.CrossRefGoogle ScholarPubMed
17.Rubin, LJ, Mendoza, J, Hood, M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (Epoprostenol): Results of a randomized trial. Ann Intern Med 1990; 112: 485–491CrossRefGoogle ScholarPubMed
18.Gomez-Sanchez, MA, De, La Calzada CS, Pajuelo, CG, et al. Different hemodynamic responses between acute and chronic infusion of Iloprost (prostacyclin-stable analogue) in severe pulmonary hypertension. Am Rev Respir Dis 1991; 144: 1404–1405CrossRefGoogle ScholarPubMed
19.Schranz, D, Zepp, F, Iversen, S, et al. Effects of tolazoline and prostacyclin on pulmonary hypertension in infants after cardiac surgery. Crit Care Med 1992; 20: 1243–1249Google ScholarPubMed
20.Higenbottam, TW, Spiegelhalter, D, Scott, JP, et al. Prostacyclin (Epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1993; 70: 366–370CrossRefGoogle ScholarPubMed
21.Barst, RJ, Rubin, LJ, Long, WA, et al. A comparison of continuous intravenous epoprostenol (Prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296–301CrossRefGoogle ScholarPubMed
22.Graham, DR, Keldermans, MM, Klemm, LW, Semenza, NJ, Shafer, ML. Infectious complications among patients receiving home intravenous therapy with peripheral, central, or peripherally placed central venous catheters. Am J Med 1991; 91: 95S–100S.CrossRefGoogle ScholarPubMed
23.Toda, N. Beraprost sodium. Cardiovasc Drug Rev 1988; 6: 222–238CrossRefGoogle Scholar
24.Takeo, S. Pharmacodynamics and clinical studies with beraprost sodium, a drug for peripheral vascular disease. Cardiovascular Drug Reviews 1992; 10: 392–403.CrossRefGoogle Scholar
25.Saji, BT, Ozawa, Y, Aoki, Y, Hashiguchi, R, Ishikira, T, Matsuo, N. Short-term hemodynamic effect of a new oral PGI2 analogue, Beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 1996; 78: 244–247.CrossRefGoogle ScholarPubMed
26.Ichida, F, Tsubata, S, Hashimoto, I, et al. Beneficial effect of beraprost sodium,-a stable analogue of prostacyclin, on pulmonary hypertension in children. Circulation 1996; 94(suppl I): I-653(abstract).Google Scholar
27.Katz, RW, Pollack, MM, Weibley, RE. Pulmonary artery carheterization in pediatric intensive care. Adv Pediatr 1984; 30: 169–190.CrossRefGoogle Scholar
28.LaFarge, CG, Miettinen, OS. The estimation of oxygen consumption. Cardiovasc Res 1970; 4: 23–30.CrossRefGoogle ScholarPubMed
29.Data, JL, Molony, BA, Meinzinger, MM, Gorman, RR. Intravenous infusion of prostacyclin sodium in man: Clinical effects and influence on platelet adenosine diphosphate sensitivity and adenosine 3': 5' -cyclic monophosphate levels. Circulation 1981; 64: 4–12.CrossRefGoogle ScholarPubMed
30.Gray, DW, Marshall, I. Novel signal transduction pathway mediating endotherium-dependenr β adrenoceptor vasorelxation in rat thoracic aorta. Br J Pharmacol 1992; 107: 684–690.CrossRefGoogle Scholar